CD86 and cancer: When antigen-presenting cells (APCs) capture cancer antigens, they increase the expression of major histocompatibility complex (MHC) and auxiliary signaling molecules such as CD80, CD86, and CD40 [3, 4], and migrate to the T-cell region of the regional lymph nodes by passing through lymph vessels in a CCR7-dependent manner [5].